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combination with a serotonin receptor antagonist (5-HT3 RA) and
dexamethasone, has demonstrated superior efficacy on end points
related to chemotherapy-induced nausea and vomiting (CINV) com-
paredwith standard care (combination 5-HT3 RA and dexamethasone).
Objective: To determine the cost-effectiveness of an aprepitant-con-
taining regimen comparedwith current clinical practice for the preven-
tion of CINV in patients receiving highly emetogenic chemotherapy
(HEC) in Singapore. Methods: A decision-analytic model was con-
tructed to assess the costs and outcomes associated with an aprepi-
ant-containing regimen compared with standard care in the preven-
ion of CINV following HEC. Three scenarios weremodeled on the basis
f results of four double-blind randomized clinical trials of aprepitant.
INV event probabilities were calculated on the basis of the occurrence
f nausea and vomiting and the need for rescue medication in the 5
ays following a single cycle of HEC. The analysis was conducted from
he Singapore health care system perspective. Results: Aprepitant re-
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doi:10.1016/j.vhri.2012.03.002duced emesis and nausea, resulting in small but clinically important
improvements when measured in quality-adjusted life-years. The
aprepitant-containing regimen was associated with higher acquisition
costs but lower costs relating to patient management, hospitalization,
and use of rescue medication. Across the scenarios, the incremental
cost per emetic event avoided ranged from cost saving to Singapore $63
(US $51). The incremental cost-effectiveness ratio ranged from cost
saving to Singapore $49,800 per quality-adjusted life-year gained (US
$40,600). The analysis was relatively insensitive to changes in the
inputs. Conclusions: Aprepitant is a clinically important and cost-
effective therapy for the prevention of CINV in patients treated with
HEC in Singapore.
Keywords: aprepitant, chemotherapy, cost-effectiveness, emesis,
Singapore.
Copyright © 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chemotherapy-induced nausea and vomiting (CINV) has been
identified as one of the most distressing adverse effects for pa-
tients who are being treated with chemotherapy for malignancy
[1]1. If CINV is not well controlled, it can significantly affect a pa-
tient’s quality of life, leading to poor compliance with further
hemotherapy treatment, which can be life-threatening. Che-
otherapies are categorized into four CINV categories accord-
ng to the emetogenic potential of the agent, namely, highly
metogenic agent (90% or more of the patients will experience
cute emesis), moderately emetogenic agent (30%–90% of the
atients will experience acute emesis), lowly emetogenic agent
10%–30% of the patients will experience acute emesis), and
inimally emetogenic agent (10% of the patients will experi-
nce acute emesis) [2]. Aprepitant, a substance P neurokinin 1
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Published by Elsevier Inc.receptor antagonist [3], is indicated for use as part of an anti-
emetic regimen for the prevention of acute and delayed CINV
associated with highly emetogenic chemotherapy (HEC) regi-
mens such as those containing cisplatin or an anthracycline
and cyclophosphamide (AC).
In clinical trials, aprepitant, in combination with a serotonin re-
ceptor antagonist (5-HT3 RA) and dexamethasone, has demon-
strated superior efficacy on end points related to CINV compared
with a standard care regimen (combination of 5-HT3 RA and dexa-
methasone) [4]. As a result, in the antiemesis guidelines issued by a
few of the key international organizations, such as theMultinational
Association of Supportive Care in Cancer, the European Society for
Medical Oncology, the National Comprehensive Cancer Network,
and the American Society of Clinical Oncology, aprepitant is recom-
mendedaspart of anantiemetic regimen forpatientswhoare receiv-
ingHEC [2,5,6]. In Singapore, aprepitant is indicated forCINVprophy-
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regimen and is not restricted for use in specific cancer types [7].
Aprepitant has been assessed and recommended for listing in
everal markets in the Asia-Pacific region. In 2009, New Zealand
dded aprepitant to its pharmaceutical schedule for patients un-
ergoing HEC or anthracycline-based chemotherapy for the treat-
ent of malignancy [8]. Similarly, aprepitant is reimbursed in
outh Korea for use with chemotherapy classified as HEC and pa-
ients receiving AC combinations [9]. In Australia, aprepitant is
ecommended for one cycle in patients undergoing chemotherapy
ith certain agents, regimens deemed to be highly emetic, and for
emale breast cancer patients receiving AC combinations [10].
A number of cost-effectiveness analyses of aprepitant have
been published [11–13]; however, the value of aprepitant in the
context of the Singapore health systemhasnot yet beendescribed.
Currently, ondansetron is included in the government standard
drug list for patients with CINV. Given that an aprepitant-based
regimen has superior efficacy, it is important to understand
whether this regimen will be cost-effective in Singapore. Our aim
was to assess the cost-effectiveness of an aprepitant-containing
regimen compared with current clinical practice for the preven-
tion of CINV in patients receiving HEC in Singapore.
Methods
Study design
Adecision-analyticmodelwas constructed inMicrosoft Excel 2002
(Microsoft Corporation, Redmond, WA) to assess the costs and
outcomes associated with aprepitant-containing regimens com-
pared with a standard regimen in the prevention of CINV in pa-
tients treated with HEC. Three scenarios were modeled by using
probabilities of response from the four randomized controlled tri-
als (Table 1).
Because the published randomized controlled trials formed the
basis of the comparison, the base-case analyses assume the same
Table 1 – Clinical trials informing the decision-analytic mo
Scenario Trial Chemotherapy
regimen
Aprepitan
1 Hesketh et al. [15]
(Protocol 052)
Cisplatin 70 mg/m2 Day 1: APT
ODN 32 m
12 mg PO
Poli-Begelli et al.
[16] (Protocol
054)
Cisplatin 70 mg/m2 Days 2–3: A
PO, DXM
PO.Day 4
PO.
2 Schmoll et al. [17]
(Protocol 801)
Cisplatin 70 mg/m2 Day 1: APT
ODN 32 m
12 mg PO
APT 80 m
8 mg PO.
8 mg PO.
3 Rapoport et al.
[18] (Protocol
130)
AC-based* Day 1: APT
ODN 8 m
DXM 12 m
2–3: APT
AC, anthracycline plus cyclophosphamide; APT, aprepitant; BID, twi
ondansetron; PO, per os (oral); QD, once daily.
* Subgroup from trial treated with AC-based regimen.patient populations and comparators as the published trials (Table1). Because granisetron is the 5-HT3 RA used in Singapore, how-
ever, a comparable granisetron dose was used in place of ondan-
setron for additional local comparator analyses. Patients enrolled
in the trials were older than 18 years with solid malignancies who
were scheduled to receive either chemotherapy that included cis-
platin (70 mg/m2) or an AC-based regimen for the first time. The
odels assess the use of aprepitant-containing regimens in these
ame patient populations.
Perspective and time horizon
The analysis was conducted from the perspective of the Singapore
health care system: direct medical costs of medications, outpatient
physician assessments, diagnostic tests and procedures, emergency
department visits, and hospitalizations were included. In line with
the clinical trial study period, which captured information up to 120
hours postchemotherapy, a 5-day (120-hour) time horizon was se-
lected for the economic analyses and assessment of CINV outcomes
relating to the first cycle of chemotherapy (Table 2).
Clinical effectiveness of aprepitant compared with standard
care
The results of the clinical trials are summarized in Table 2. Com-
plete response was defined as no vomiting and no use of rescue
medications, and patients who did not achieve complete response
were considered to be incomplete responders. CINV is classified
according to the time since administration of chemotherapy; the
acute phase occurs between 0 and 24 hours of administration, and
the delayed phase lasts from more than 24 to 120 hours. As re-
ported by Warr and colleagues [14], the data from protocols 052
and 054were pooled for scenario 1 because of the similarity in trial
design, patient population, and antiemetic regimens.
In all trials, aprepitant demonstrated a statistically significant
benefit in terms of complete response in the overall phase, as well
as in the acute and delayed period.
The antiemetic prophylaxis regimens used in the aprepitant
imen Comparator regimen Primary end point
g PO,
, DXM
Single-day 5-HT3
comparatorDay 1: ODN
32 mg IV (GTN 3 mg IV
Proportion of patients with
complete response,
overall phase.
mg
8 mg
for local standard care),
DXM 20 mg PO.Days 2–4:
DXM 8 mg PO BID.
g PO,
, DXM
s 2–3:
, DXM
: DXM
Multiday (days 2–4) 5-HT3
comparatorDay 1: ODN
32 mg IV (GTN 3 mg IV
for local standard care),
DXM 20 mg PO.Days 2–4:
ODN 8 mg PO BID or
GTN 1 mg PO BID, DXM
8 mg PO BID.
Proportion of patients with
complete response,
overall phase.
g PO,
BID,
.Days
g PO.
Day 1: ODN 8 mg PO BID
(GTN 1 mg PO BID for
local standard care),
DXM 20 mg PO.Days 2–3:
ODN 8 mg PO BID or
(GTN 1 mg PO BID for
local standard care).
Proportion of patients with
no emesis, overall phase.
ily; DXM, dexamethasone; GTN, granisetron; IV, intravenous; ODN,del.
t reg
125 m
g IV
.
PT 80
8 mg
: DXM
125 m
g IV
.Day
g PO
Day 4
125 m
g PO
g PO
80 m
ce daclinical trials [15–18] represent the standard regimens in
t
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RA of choice. For the purpose of the analysis, these agents were
assumed to be equivalent in terms of efficacy and safety. This
assumption is supported by a recent meta-analysis of the use
of ondansetron and granisetron for acute-phase CINV prophy-
laxis [19].
Model structure
The model uses a previously published decision-tree structure
that includes health states that reflect the potential unique com-
binations of day 1 (acute-phase) and days 2 to 5 (delayed-phase)
outcomes [12].Model health stateswere based on the endpoints in
he clinical trials and included “Complete Protection,” “Complete
esponse at Best,” and “Incomplete Response.” In the trials, the
nd point “Complete Response” was defined as no emesis and no
se of rescue therapy, while Complete Protection was a subset of
omplete responders with a low nausea score of less than 25 mm
n a 100-mm nausea visual analogue scale (0  “no nausea” and
100 “nausea as bad as it can be”). Thus, for mutually exclusive
health states, Complete Response at Best was defined as no eme-
sis, no rescue therapy, and a maximum reported nausea score of
25mmormore on the 100-mmvisual analogue scale. Patientswho
experienced some emesis or use of rescue therapywere deemed to
have an Incomplete Response.
Model health state probabilities
The CINV probabilities were calculated from amodified intention-
to-treat population, based onpatients’ diary entries for episodes of
vomiting/retching, daily nausea reported on the visual analogue
scale, and use of rescue medication. The resultant health state
probabilities are reported in Table 3.
Table 2 – Summary of clinical trial evidence for an aprepita
Scenario Patients and comparator Regime
1 Cisplatin regimen, with single-day
5-HT3 RA as SC [12,13]
Aprepitant
SC
Difference (P
2 Cisplatin regimen, with 4-d 5-HT3
RA as SC [14]
Aprepitant
SC
Difference (P
3 AC regimen with 3-d 5-HT3 RA as
SC [15]
Aprepitant
SC
Difference (P
5-HT3 RA, 5HT3 receptor antagonist; AC, anthracycline plus cyclopho
Table 3 – Probabilities used in the model.
Scenario Trial Acute phase
Delayed phase
CP
1 Cisplatin regimen, with
single-day 5-HT3 RA
as SC [13,14]
Aprepitant (n  514) 306 (59.5)
SC (n  518) 231 (44.6)
2 Cisplatin regimen, with
4-d 5-HT3 RA as SC
[15]
Aprepitant (n  242) 150 (62.0)
SC (n  237) 133 (56.1)
3 AC regimen with 3-d
5-HT3 RA as SC [16]
Aprepitant (n  193) 112 (58.0)
SC (n  201) 80 (39.8)
AC, anthracycline plus cyclophosphamide; CP, complete protection
antagonist; SC, standard care.Estimation of utility values
Utility data were not collected in the clinical trials, and unfortu-
nately there is little published information available to informutil-
ity weights for CINV health states. The model maps published
utility values that were derived from the CINV literature to the
relevant model health states [12]. The Complete Protection state
was assigned a utilityweight of 0.9, Complete Response at Best 0.7,
and Incomplete Response 0.2 [20]. These values have also been
used to estimate the utility weights in previous publications on
this topic [12,21]. The utility weights are applied constantly for the
duration of the health state, where the acute period health state is
1 day (24 hours) and the delayed period health state is 4 days (96
hours). The 5-day quality-adjusted life-year (QALY) totals were
calculated by using the following formula: (QALY weight/365)  5.
Given the paucity of information available to inform the utility
estimates, sensitivity analysis was undertaken on these parame-
ters to determine how changes in these would affect the results.
Use and costs of medical resources
Costs
Resource use associated with each health state was informed by
the pooled patient-level data obtained from the diaries of patients
in the randomized controlled trials. Hospital-related and medical
treatment costs were sourced from the Tan Tock Seng Hospital
and the National Cancer Centre Singapore, the two largest cancer
institutions in Singapore. Hospitalization costs relate to admission
for severe CINV, and this cost includes fees for specialist consul-
tations, duration of inpatient stay, admission and discharge, blood
tests, and daily antiemetic medications for 3 days. In Singapore,
there is a standard fee of Singapore S $83 to S $90 for all presenta-
ontaining regimen compared with standard care.
Overall CR Acute CR Delayed CR
68.0% 86.0% 72.0%
48.0% 73.0% 51.0%
e) 20.0% (P  0.001) 13.0% (P  0.001) 21.0% (P  0.001)
72.0% 87.7% 74.1%
60.6% 79.3% 63.1%
e) 11.4% (P  0.003) 8.4% (P  0.005) 11.0% (P  0.004)
62.8% 84.3% 64.8%
47.1% 72.5% 52.9%
e) 15.7% (P  0.05) 11.8% (P  0.05) 11.9% (P  0.05)
mide; CR, complete response; SC, standard care.
n (%)
P CRB IR
RB IR CP CRB IR CP CRB IR
(5.6) 88 (17.1) 4 (0.8) 8 (1.6) 6 (1.2) 17 (3.3) 3 (0.6) 53 (10.3)
(1.5) 121 (23.4) 2 (0.4) 5 (1.0) 12 (2.3) 13 (2.5) 5 (1.0) 121 (23.4)
(6.6) 36 (14.9) 4 (1.7) 4 (1.7) 2 (0.08) 4 (1.7) 1 (0.4) 25 (10.3)
(3.0) 42 (17.7) 0 (0.0) 2 (0.8) 3 (1.3) 5 (2.1) 1 (0.4) 44 (18.6)
(2.6) 34 (17.6) 0 (0.0) 5 (2.6) 8 (4.1) 2 (1.0) 2 (1.0) 25 (13.0)
(4.5) 46 (22.9) 2 (1.0) 4 (2.0) 5 (2.5) 10 (5.0) 2 (1.0) 43 (21.4)
, complete response at best; IR, incomplete response; RA, receptornt-c
n
valu
valu
valuC
C
29
8
16
7
5
9
; CRB
$
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visit in the model was informed by the Singapore Medical Associ-
ation’s recommended consultation fee.
For the cisplatin-based regimens (scenarios 1 and 2), average re-
source usewas estimated by using the data from the 052/054 (cispla-
tin-based regimens) clinical trials. Protocol 130 (AC regimen) cap-
tured costs relating to only the use of rescue medications and
hospitalizations. Therefore, the average use of other resources for
Table 4 – Costs of prophylactic CINV regimens used in
the trials and resources used in the analysis.
Description of regimen/resource Cost
(SGD 2010*)
Reference
Scenario 1: Cisplatin regimen with
single-day 5-HT3 RA as
comparator, Protocol 052/054
Aprepitant-containing regimen 138.77 MSD, Singapore
Standard care regimen
Using ondansetron 42.74 TTSH and NCC
Using granisetron 40.44
Scenario 2: Cisplatin regimen with
4-d 5-HT3 RA as comparator,
Protocol 801
Aprepitant-containing regimen 138.77 MSD, Singapore
Standard care regimen
Using ondansetron 42.74 TTSH and NCC
Using granisetron 40.44
Scenario 3: AC regimen with 3-d
5-HT3 RA as comparator,
Protocol 130
Aprepitant-containing regime 124.08 MSD, Singapore
Standard care regimen
Using ondansetron 42.74 TTSH and NCC
Using granisetron 40.44
Medications
Aprepitant
125 mg per tablet 32.33 MSD, Singapore
80 mg per tablet 32.33
Ondansetron
8 mg per tablet 5.46 TTSH and NCC
32 mg IV 40.70
Granisetron
3 mg IV 38.40
1 mg per tablet 11.35
Dexamethasone
4 mg per tablet 0.12
20 mg per tablet 0.62
Rescue medications
Metoclopramide (75%)
10 mg IV 1.67
Ondansetron (25%)
8 mg per tablet
Hospital resources
Hospitalization
Episode 1367.92 TTSH and NCC
Emergency department
Visit 85.00
Medical specialist
Visit 69.60
General practitioner
Visit 35.00 Singapore Medical
Association
AC, anthracycline plus cyclophosphamide; CINV, chemotherapy-
induced nausea and vomiting; IV, intravenous; NCC, National Can-
cer Centre; RA, receptor antagonist; SGD, Singapore dollar; TTSH,
Tan Tock Seng Hospital.
* Exchange rate: SGD 1  US $0.8153 on July 1, 2011.scenario 3was assumed to be similar to the resource use reported in
another trial that enrolled patients treated with AC [14].
A description of the resources included in the analysis and the
unit costs (Singapore dollars) are shown in Table 4. No dispensing
fees were included because, in Singapore, these are not charged for
prescriptions that have been issued during a consultation. Similarly,
the costs used in the model already included all relevant markups,
and so no additional markups were included. The resultant costs of
theCINVregimensused in theclinical trials and for eachscenarioare
shown in Table 5. For a comparisonwith US dollars, the results were
converted by using the exchange rate on July 1, 2011: S $1  US
0.8153 [22]. Because the timehorizon of the analysiswas 5 days (the
ength of the clinical trial), no discount rate was applied to the costs.
Sensitivity analysis
One-way sensitivity analysis was conducted to determine how
changes in key variables affected the results. The acquisition prices
for the 5-HT3 RA antiemetics and the utility weights associatedwith
complete response and nausea and emetic episodes were also var-
ied. For each scenario, two-way sensitivity analysis was then under-
taken to assess the impact of varying the two inputs that had the
greatest effect on the one-way sensitivity analysis results.
Results
The base-case results for the three scenarios modeled are shown
in Table 6.
Interpretation and comparison of the results
In all scenarios modeled, aprepitant demonstrated a reduction in
emetic events per patient, which translated into improved quality
of life, measured in quality-adjusted life-days and QALYs. The dif-
Table 5 – Cost of prophylactic CINV regimens used in
the clinical trials.
CINV regimen Cost
(SGD 2010*)
Reference
Scenario 1: Cisplatin regimen with
single-day 5-HT3 RA as
comparator, Protocol 052/054
Aprepitant-containing regimen 138.77 MSD, Singapore
Standard care regimen
Using ondansetron 42.74 TTSH and NCC
Using granisetron 40.44
Scenario 2: Cisplatin regimen with
4-d 5-HT3 RA as comparator,
Protocol 801
Aprepitant-containing regimen 138.77 MSD, Singapore
Standard care regimen
Using ondansetron 42.74 TTSH and NCC
Using granisetron 40.44
Scenario 3: AC regimen with 3-d
5-HT3 RA as comparator,
Protocol 130
Aprepitant-containing regimen 124.08
Standard care regimen
Using ondansetron 42.74 TTSH and NCC
Using granisetron 40.44
AC, anthracycline plus cyclophosphamide; CINV, chemotherapy-in-
duced nausea and vomiting; NCC, National Cancer Centre Singapore;
RA, receptor antagonist; SGD, Singapore dollar; TTSH, Tan Tock Seng
Hospital.
* Exchange rate: SGD 1  US $0.8153 on July 1, 2011.ference in QALYs was small due to the short time horizon.
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includingaprepitantwere similar for the cisplatin-based chemother-
apy regimens: S $226.41 (US $184.59) for scenario 1 and S $223.65 (US
$182.34) for scenario 2. The aprepitant arm in scenario 3, for the AC-
based chemotherapy, cost less at S $124.08 (US $101.16). Because
granisetron ismore expensive than ondansetron, regimens contain-
ing granisetron as the 5-HT3 RA were more expensive.
For the aprepitant arm, the cost of the prophylaxis regimen
was the main contributor to the total cost per patient. In compar-
ison, patient management costs, which included costs associated
with hospitalizations, visits to emergency department, medical
specialist, or general practitioner,were themain contributor to the
total cost per patient in the standard care arm.
The incremental cost per emetic event avoided ranged from
cost-saving when granisetron was used as the 5-HT3 RA in pa-
Table 6 – Results of the base-case analysis (in SGD).
Outcome Aprepitan
reg
Scenario 1: Cisplatin regimen with single-day 5-HT3
RA as comparator, Protocol 052/054
Total cost per patient† 22
Emetic events per patient
QALDs
QALYs
Incremental cost per emetic event avoided
(ondansetron SC regimen)
Incremental cost per emetic event avoided
(granisetron SC regimen)
Incremental cost per QALY gained (ondansetron
SC regimen)
Incremental cost per QALY gained (granisetron SC regimen)
Scenario 2: Cisplatin regimen with 4-d 5-HT3 RA as
comparator, Protocol 801
Total cost per patient† 22
Emetic events per patient
QALDs
QALYs
Incremental cost per emetic event avoided
(ondansetron SC regimen)
Incremental cost per emetic event avoided
(granisetron SC regimen)
Incremental cost per QALY gained (ondansetron
SC regimen)
Incremental cost per QALY gained (granisetron SC
regimen)
Scenario 3: AC regimen with 3-d 5-HT3 RA as
comparator, Protocol 130
Total cost per patient† 12
Emetic events per patient
QALDs
QALYs
Incremental cost per emetic event avoided
(ondansetron SC regimen)
Incremental cost per emetic event avoided
(granisetron SC regimen)
Incremental cost per QALY gained (ondansetron
SC regimen)
Incremental cost per QALY gained (granisetron SC
regimen)
AC, anthracycline plus cyclophosphamide; QALD, quality-adjusted
standard care; SGD, Singapore dollar.
* Ondansetron was the 5-HT3 RA used in the aprepitant-containing
† Prophylactic regimen and medical resource use.tients receiving AC-based chemotherapy to S $63 (US $51) whenondansetron was used as the 5-HT3 RA in patients receiving a
cisplatin-based chemotherapy regimen. The incremental cost-ef-
fectiveness ratio (ICER) ranged from cost saving to S $49,800 (US
$40,600) per QALY gained for these same scenarios.
Sensitivity analysis
Table 7, 8, and 9 show the results from both one-way and two-way
sensitivity analyses. The analysis was relatively insensitive to
changes in the cost inputs. Reducing the cost of ondansetron did
not appreciably affect the cost-effectiveness of aprepitant. For the
cisplatin regimen with a multiday 5-HT3 RA as comparator (sce-
nario 2), the analysis was sensitive to changes in the cost of gran-
isetron; however, the cost per QALY remained under S $50,000.
Sensitivity analysis also tested the effect of lowering the costs
ntaining
n*
Standard care Difference
Ondansetron Granisetron
143.27 140.97 —
1.63 3.07 1.44
2.90 0.63
67 0.00796 0.00172
58
68
48,440
49,778
168.35 201.39 —
2.40 0.88
3.26 0.34
88 0.00894 0.00094
$\63
$\25
$\58,719
$\22,636
97.95 133.29 —
2.60 0.29
2.91 0.45
2 0.0080 0.0012
91
Cost-saving
21,421
Cost-saving
ay; QALY, quality-adjusted life-year; RA, receptor antagonist; SC,
ens as per the protocols in the clinical trials.t-co
ime
6.41
3.53
0.009
3.65
1.52
3.61
0.009
4.08
2.32
3.36
0.009
life-d
regimrelating to hospitalization and specialist and general practitioner
Table 7 – One-way sensitivity analysis for ondansetron.
Parameters
20% lower cost of
ondansetron (8
mg per tab: from
S $5.46 to $4.37;
32 mg IV: from
S $40.70 to $32.56)
Generic ondansetron*
(8 mg per tab: from
S $5.46 to $2.23)
50% higher utility
for IR state (from
0.2 to 0.3)
Utility value
for CP state
(from 0.9 to
0.79)
16% lower
hospitalization
cost† (from
S $1,367.92 to
S $1,149.05)
Lower medical
specialist
charges (from
S $69.60 to $50)
Lower GP visit cost
(from S $35 to
S $25)
Scenario 1: Cisplatin regimen with
single-day 5-HT3 RA as
comparator, Protocol 052/054‡
Incremental cost per QALY S $48,438 S $48,438* S $57,029 S $56,046 S $49,166 S $48,525 S $48,465
Absolute change from base case S $2 S $2 S $8,589 S $7,606 S $766 S $125 S $65
% change from base case 0.004% 0.004% 17.73% 15.70% 1.58% 2.6% 0.13%
Scenario 2: Cisplatin regimen with
4-d 5-HT3 RA as comparator,
Protocol 801
Incremental cost per QALY S $65,664 S $79,298 S $69,851 S $66,107 S $59,560 S $58,784 S $58,754
Absolute change from base case S $6,945 S $20,579 S $11,132 S $7,388 S $841 S $65 S $35
% change from base case 11.83% 35.05% 18.6% 12.58% 1.43% 0.11% 0.059%
Scenario 3: AC regimen with 3-d
5-HT3 RA as comparator,
Protocol 130
Incremental cost per QALY S $21,421 S $32,015 S $24,922 S $25,615 S $21,421 S $21,479 S $21,446
Absolute change from base case 0 S $10,594 S $3,501 S $4,194 S $636 S $58 S $25
% change from base case 0% 49.46% 16.34% 19.58% 2.97% 0.27% 0.12%
AC, anthracycline plus cyclophosphamide; CP, complete protection.
GP, general practitioner; IR, incomplete response; IV, intravenous; QALY, quality-adjusted life-year; RA, receptor antagonist; tab, tablet.
* Generic ondansetron IV is not available in Singapore.
† The 16% estimation is based on the variance between the published lowest cost of a hospital ward charge in Singapore and the average pooled costs from the two hospitals in the analysis.
‡ For scenario 1, the regimens do not contain ondasetron IV only on day 1, no subsequent intake of oral ondansetron.
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Table 8 – One-way sensitivity analysis for granisetron.
Parameters
20% lower cost of
granisetron (1 mg
per tab: from
S $11.35 to S $9.08;
3 mg IV: from
S $40.70 to
S $30.72)
Generic granisetron
(not available in
Singapore)
50% higher utility
for IR state (from
0.2 to 0.3)
Utility value for
CP state (from
0.9 to 0.79)
16% lower hospitalization
cost* (from S $1,367.92 to
S $1,149.05)
Lower medical
specialist
charges (from
S $69.60 to $50)
Lower GP
visit cost
(fromS $35
to S $25)
Scenario 1: Cisplatin regimen with
single-day 5-HT3 RA as
comparator, Protocol 052/054
Incremental cost per QALY S $54,252 — S $58,606 S $57,596 S $50,506 S $49,865 S $49,805
Absolute change from base case S $4,474 8,828 S $7,818 S $728 S $87 S $27
% change from base case 8.99% — 17.73% 15.71% 1.46% 0.17% 0.05%
Scenario 2: Cisplatin regimen with
4-d 5-HT3 RA as comparator,
Protocol 801
Incremental cost per QALY S $46,253 — S $28,117 S $26,610 S $24,477 S $23,700 S $23,671
Absolute change from base case S $23,617 S $5,481 S $3,974 S $1,841 S $1,064 S $1,035
% change from base case 104.33% — 24.21% 17.56% 8.13% 4.70% 4.57%
Scenario 3: AC regimen with 3-d
5-HT3 RA as comparator,
Protocol 130
Incremental cost per QALY S $3,612 — Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving
Absolute change from base case From cost saving — — — — — —
% change from base case From cost saving to
S$3,612 per QALY
gained
— — — — — —
AC, anthracycline plus cyclophosphamide; CP, complete protection; GP, general practitioner; IR, incomplete response; IV, intravenous; QALY, quality-adjusted life-year; RA, receptor antagonist; tab,
tablet.
* The 16% estimation is based on the variance between the published lowest cost of a hospital ward charge in Singapore and the average pooled costs from the two hospitals in the analysis.
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change in ICERs was small (5%), demonstrating that the analysis
is not sensitive to changes in these inputs.
To assess the effect of lower quality-of-life improvements from
treatment, the utility weight for Incomplete Response rate was in-
creasedandtheutilityweight forCompleteProtectionwasdecreased in
the sensitivity analysis. When the utility for Incomplete Response was
increased to 0.3, the change in the results (up to 24%)was less than the
variation in the initial input (50%), indicating that the analysis is rela-
tively robust to changes in theutilityweight assigned to the Incomplete
Response health state. If the utility of Complete Responsewas reduced
to 0.79, decreasing the benefit of aprepitant bymore than12%, the ICER
for aprepitant increased up to S $66,000 per QALY gained.
Based on the results from the one-way analysis, a “worst-case”
two-way sensitivity analysis was conducted for each scenario by si-
multaneously varying the two inputs that had produced the greatest
change in the one-way sensitivity analysis. For the two-way sensi-
tivity analysis, when ondansetron was the comparator, the highest
cost per QALY result reached S $94,000. When granisetron was the
comparator, the ICER reached a maximum of S $64,000. It should be
noted, however, that these are worst-case analyses and may not be
representative of the current situation in Singapore.
Discussion
CINV has been identified as one of the most distressing adverse
effects for patients who are being treated with chemotherapy for
malignancy, with patients rating the nausea or vomiting as low as
Table 9 – Two-way sensitivity analysis for ondansetron an
Description
Ondansetron analyses
Scenario 1: Cisplatin regimen with single-day 5-HT3 RA as
comparator, Protocol 052/054
Incremental cost per QALY
Absolute change from base case
% change from base case
Scenario 2: Cisplatin regimen with 4-d 5-HT3 RA as
comparator, Protocol 801
Incremental cost per QALY
Absolute change from base case
% change from base case
Scenario 3: AC regimen with 3-d 5-HT3 RA as comparator,
Protocol 130
Incremental cost per QALY
Absolute change from base case
% change from base case
Granisetron analyses
Scenario 1: Cisplatin regimen with single-day 5-HT3 RA as
comparator, Protocol 052/054
Incremental cost per QALY
Absolute change from base case
% change from base case
Scenario 2: Cisplatin regimen with 4-d 5-HT3 RA as
comparator, Protocol 801
Incremental cost per QALY
Absolute change from base case
% change from base case
Scenario 3: AC regimen with 3-d 5-HT3 RA as comparator,
Protocol 130
Incremental cost per QALY
Absolute change from base case
% change from base case
AC, anthracycline plus cyclophosphamide; CP, complete protection; IR, inc0.2 on a visual acuity scale [1]. Aprepitant has demonstrated aclinically important improvement of up to 20% in the proportion of
patients protected from acute or delayed emesis after treatment
with HEC [15,16]. Our results support that achieving this clinical
improvement with aprepitant is also cost-effective in the context
of the Singapore health system, with a favorable cost per emetic
event avoided and cost per QALY result.
Singapore does not have a published threshold to determine
cost-effectiveness.We can, however, compare our resultswith the
commonly quoted international standards, which include a cutoff
at US $50,000 (S $64,000), and the threshold endorsed by theWorld
Health Organisation of up to three times gross domestic product
per capita (S $ 160,000) per QALY gained.
In this context, our analysis of the use of aprepitant for cisplatin-
basedchemotherapyregimens (Protocols052/054and801) indicate that
anaprepitant-containingregimeniscost-effective (with ICERsclose toS
$50,000) for use in these patients compared with standard regimens
including ondansetron or granisetron. These analyses indicated that
aprepitant results in cost-offsets due to reduced costs of patient man-
agement and hospitalization, and lower use of rescuemedication.
Our results are novel in the assessment of Protocol 130 (scenario 3);
thecost-effectivenessofaprepitant forAC-containingregimenshasnot
been reportedelsewhere. In this scenario, aprepitantwas cost-effective
in patients receiving AC-based chemotherapy compared with a stan-
dard regimen includingondansetronas the5-HT3RA,withan ICERofS
$21,400, and cost-saving if granisetronwas used in standard care.
Our results are also consistentwith those published elsewhere in
the literature. Lordick and colleagues [12] developed a decision ana-
lyticmodel to assess the cost-effectiveness of aprepitant inGermany
anisetron.
Two-way sensitivity analysis (“worst case”) (SGD)
lower cost of ondansetron and 50% higher utility for IR state  0.3
57,029
8,589
17.73%
dansetron oral generic and 50% higher utility for IR state  0.3
94,330
35,611
60.65%
dasetron oral generic and utility value for CP state  0.79
38,282
16,861
78.71%
lower cost of granisetron and 50% higher utility for IR state  0.3
63,874
14,096
28.32%
lower cost of granisetron and 50% higher utility for IR state  0.3
55,022
32,386
143.07%
lower cost of granisetron and 50% higher utility for IR state  0.3
4,203
m cost-saving to 4,203 per QALY gained
m cost-saving to 4,203 per QALY gained
ete response; QALY, quality-adjusted life-year; RA, receptor antagonist.d gr
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regimenwas associatedwith anadditional 15hours of perfect health
per cycle (0.63 quality-adjusted life-days) compared with standard
care. The resultant ICERwasestimatedat ’8028,900 (S $49,700),which
is in line with our results for scenario 1.
An article from Belgium reported the findings from a cost-utility
analysis based on the results of Protocols 052/054 (cisplatin-based regi-
men)and801(ACregimen) [11].Anadditional scenariouseddata froma
ongitudinal hospital database to provide information on real-world re-
ourceuse inCINV. In both scenarios, the authors found the aprepitant
o be cost saving (less costly andmore effective) than standard care in
oth highly andmoderately emetic chemotherapy regimens.
The cost-effectiveness of aprepitant in the United States was as-
essed by using a Markov model to compare an aprepitant-contain-
ng regimenwitha standard regimenof ondansetronanddexameth-
sone over five cycles of chemotherapy [13]. The resultant ICER was
high (US $96,300); however, it should be noted that the costs of the
antiemetic treatment regimensweremore thandouble thoseused in
our analysis.
There are some limitations to our approach. First, the resource use
dataweredrawnfromthosereportedinclinical trials (Protocols052/054,
cisplatin-based regimens) rather than Singapore-specific resource use.
Although itwould be preferable to use country-specific data, this is not
routinely reported for Singapore and, in the absence of good informa-
tion,makingassumptionswouldhave introduceduncertainty. Second,
the clinical data were collected by using patient diaries and therefore
this information is subjective in nature. However, because there are no
objectivemeasures for CINVendpoints, the diaries are valuable in that
theycapturetheseverityofCINVforanindividual.Third,therewaslittle
informationtoinformtheutilityestimatesforhealthstatesinthemodel
becausehealth-relatedquality-of-lifedatawerenotcollectedintheclin-
ical trials. Therefore, the best available estimates includedwere drawn
from the literature, and thesewere a key focus of the sensitivity analy-
sis.Currently, thereisanemesisregistrycalledthePRACTICEstudy(The
Pan Australasian Chemo Therapy Indu Ced Emesis burden of illness
study) ongoing in six countries, namely, Singapore, India, China, Aus-
tralia, Taiwan, and South Korea. Medical resource use costs are cap-
tured in this trial and will provide useful information on the compara-
tive costs of treating CINV in Asia. In addition, the EuroQol five-
dimensionalquestionnaireutilitymeasure is included in this studyand
asa resultwewill potentiallyhaveutility scores forHECpatients inAsia
when this study data become available. Finally, we did not undertake
probabilistic sensitivity analysis to quantify the level of confidence in
the ICERs. Instead, two-waysensitivityanalysiswasconducted foreach
scenario by simultaneously varying the two inputs that had produced
the greatest change in the one-way sensitivity analysis. These results
represent a “worst-case” and a “best-case” analysis, whichmay not be
representative of the current situation in Singapore.
Conclusions
Aprepitant is a clinically important and cost-effective treatment
compared with the usual standard of care for the prevention of
CINV in patients treated with HEC in Singapore.
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